HOMEPAGE
Fully Diluted Subscribe

Nasdaq · Biotech stocks database

CNTX — Context Therapeutics Inc.

CNTX (Context Therapeutics Inc.) stock: $0.20, $43.0M cash, $21.9M fully diluted market cap. Next expected readout: May-28. Lead program: CTIM-76 (Platinum-resistant Ovarian Cancer), Phase 1. Data from Fully Diluted's biotech stocks database.

What they do

We are a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies (“bsAb”) for solid tumors. Our goal is to build an innovative portfolio of TCE bispecific therapeutics, including CTIM-76, a Claudin 6 (“CLDN6”) x CD3 TCE, CT-95, a Mesothelin (“MSLN”) x CD3 TCE, and CT-202, a Nectin cell adhesion protein 4 (“Nectin-4”) x CD3 TCE.

Source: 10-K FY2025 via SEC EDGAR

Share price
$0.20
Market cap
Not disclosed
Cash
$43.0M
Enterprise value
Not disclosed

Balance sheet

Cash$43.0M
Debt$0.0M
Net cash$43.0M
Enterprise valueNot disclosed
Basic shares91.9M shares
Fully diluted shares109.7M shares
Fully diluted market cap$21.9M
Cash per share$0.47
Quarterly burn$7.0M
Cash runway6.1 quarters

Cash figures as of 2026-06-30. Database snapshot: 2026-11-11.

Share structure

Common
91.9M
Pre-funded warrants
3.3M
Options
8.6M
RSUs
0.0M
Warrants
5.9M
Converts
0.0M
Conv preferred
0.0M
ESPP reserve
—
FDSO
109.7M

Cap table as of 2026-06-30.

Price history

Loading CNTX daily closes…

Loading price history…

Next catalyst

CT-95 · Jan 12 - Feb 23 in 9 wks · Phase 1 · Mesothelin-Expressing Tumors; Epithelial Ovarian Cancer; Malignant Pleural Mesothelioma, Advanced

Recently reported

CTIM-76 Phase 1 Positive · 2026-11-10
CTIM-76 · platinum-resistant ovarian cancer, testicular cancer, endometrial cancer
Primary: Confirmed objective response rate in efficacy-evaluable patients with platinum-resistant ovarian cancer (PROC) treated at biologically active weekly doses of CTIM-76 (140-280 µg), with median PFS — Confirmed ORR 22% and disease control rate 56% (2 confirmed partial responses, 3 stable disease) among n=9 efficacy-evaluable PROC patients treated weekly at 140-280 µg; median PFS 5.6 months (95% CI: 1.2-7.4 months)
· 27 patients dosed as of October 30, 2026 (ovarian n=20, testicular n=4, endometrial n=3); weekly dosing 22.5 to 560 µg (n=21) or every-three-week dosing at 280 µg (n=6)
· Patients with PROC at biologically active doses had received a median of 6 prior lines of therapy (range, 3-16); 12 (80%) had received a prior antibody-drug conjugate
· All seven liver target lesions decreased in size (median -58%; range -16% to -100%), including two that disappeared completely
· DLT assessment period at 280 µg every three weeks complete (n=6); dose escalation to 420 µg every three weeks ongoing
· Phase 1b dose expansion initiation expected Q1 2027; initial every-three-week efficacy data in PROC expected Q2 2027
Safety: Cytokine release syndrome in 5 of 27 patients (18.5%), all Grade 1 or 2; Grade ≥3 treatment-emergent adverse events in 22 of 27 patients (81.5%), most commonly increased GGT (37.0%), AST (29.6%) and ALT (22.2%); Grade ≥3 liver enzyme elevations were dose-related, generally occurred early, and resolved with continued dosing
Source release →
Get the weekly biotech catalyst rundown.
Cash runways, financings, and trial readouts for all 718 stocks.
Subscribe to Compounding Ego